Zacks Research Predicts TSE:ONC FY2026 Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at Zacks Research issued their FY2026 earnings estimates for Oncolytics Biotech in a research note issued to investors on Tuesday, April 7th. Zacks Research analyst D. Bautz forecasts that the company will earn ($0.33) per share for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for Oncolytics Biotech’s FY2027 earnings at ($0.32) EPS and FY2028 earnings at ($0.29) EPS.

Oncolytics Biotech Stock Down 1.3%

Oncolytics Biotech stock opened at C$14.90 on Wednesday. The stock has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a twelve month low of C$0.44 and a twelve month high of C$2.08. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The company has a 50 day moving average of C$14.90 and a 200-day moving average of C$14.90.

Insider Buying and Selling

In related news, Director Bernd Robert Seizinger purchased 60,000 shares of Oncolytics Biotech stock in a transaction dated Wednesday, February 11th. The stock was bought at an average price of C$1.14 per share, for a total transaction of C$68,400.00. Following the completion of the acquisition, the director directly owned 526,991 shares of the company’s stock, valued at C$600,769.74. This represents a 12.85% increase in their ownership of the stock. Also, insider Andrew P. Aromando purchased 29,600 shares of Oncolytics Biotech stock in a transaction dated Wednesday, February 11th. The stock was bought at an average price of C$1.18 per share, with a total value of C$34,928.00. Following the acquisition, the insider directly owned 55,100 shares of the company’s stock, valued at approximately C$65,018. This trade represents a 116.08% increase in their ownership of the stock. Over the last three months, insiders have acquired 289,232 shares of company stock valued at $335,760. 3.82% of the stock is owned by corporate insiders.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.